Pancreatic Cancer Therapy Market to Reach US$ 4,056.4 Million at CAGR of 8.1% by 2025 | The Insight Partners

Pancreatic Cancer Therapy Market to 2025 - Global Analysis and Forecasts By Type (Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer), Therapy (Biology, Chemotherapy and Others) and Geography

Publication Month: Aug 2018 | Report Code: TIPMD00002009 | No. of Pages: 133 | Category: Medical Device | Status: Published
Covid

The pancreatic cancer therapy market is expected to reach US$ 4056.4 million by 2025 from US$ 2011.2 million in 2017; it is estimated to grow at a CAGR of 8.1% from 2018 to 2027.

Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.

Lucrative Regional Markets for Pancreatic Cancer Therapy

Lucrative Regional Markets for Pancreatic Cancer Therapy

Get more information on this report :



Market Insights

Rise in Number of Patients Suffering with Pancreatic Cancer

Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer. The cancer is almost always fatal and thus demands potential therapies for the patients’ treatment. For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the global pancreatic cancer therapy market over the forecast years.

 

Type Insights

Based on type, the pancreatic cancer therapy market is segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.

 

Global Pancreatic Cancer Therapy Market, by Type – 2017 and 2025

Global Pancreatic Cancer Therapy Market, by Type – 2017 and 2025

Get more information on this report :


 

Therapy Insights

Based on therapy, the pancreatic cancer therapy market is segmented into biologic therapy, chemotherapy, and others. In 2017, biologic therapy segment held the largest share of the market, by therapy. Moreover, the biologic therapy segment is expected to grow at the fastest rate during the coming years owing to increasing number of novel upcoming immunotherapies as well as targeted cell therapy that treats the cancer without any severe side effects and has number of therapeutic benefits over the conventional chemotherapies.

 

Strategic Insights

 

Organic strategies are the more commonly adopted strategies by companies in the pancreatic cancer therpay market, which enables them expand their global footprints, and product and service portfolios. The market players have also adopted organic strategies such as product approvals, clinical trials and others strategies have enabled them to enlarge their global customer base, which also permits them to maintain their brand name globally.

 

Global Pancreatic Cancer Therapy Market – By Type

  • Exocrine Pancreatic Cancer
  • Endocrine Pancreatic Cancer

Global Pancreatic Cancer Therapy Market– By Therapy

  • Biologics Therapy
  • Chemotherapy
  • Others

Global Pancreatic Cancer Therapy Market– By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
  • South and Central America
    • Brazil
    • Argentina

 

Company Profiles

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Novartis AG
  • Celgene Corporation
  • Merck & Co., Inc
  • Pharmacyte Biotech Inc
  • Clovis Oncology
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc

TABLE OF CONTENTS

1. INTRODUCTION 18
1.1 SCOPE OF THE STUDY 18
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 18

2. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY TAKEAWAYS 19

3. GLOBAL PANCREATIC CANCER THERAPY MARKET - MARKET LANDSCAPE 21
3.1 OVERVIEW 21
3.2 MARKET SEGMENTATION 21
3.3 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY TYPE 22
3.4 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY THERAPY 22
3.5 GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY 23
3.6 PEST ANALYSIS 24
3.6.1 North America - PEST Analysis 24
3.6.2 Europe- PEST Analysis 26
3.6.3 Asia Pacific- PEST Analysis 28
3.6.4 Middle East And Africa- PEST Analysis 30
3.6.5 South and Central America - PEST Analysis 32

4. GLOBAL PANCREATIC CANCER THERAPY MARKET - KEY MARKET DYNAMICS 34
4.1 KEY MARKET DRIVERS 34
4.1.1 Rise in Number of Patients Suffering with Pancreatic Cancer 34
4.1.2 Increasing Healthcare Expenditures for Pancreatic Drugs 34
4.1.3 Increase in Number of Therapies Launched in the Market 35
4.2 KEY MARKET RESTRAINTS 35
4.2.1 Side Effects of the Therapies 35
4.2.2 Low Success Rate of Treatments 35
4.3 KEY MARKET OPPORTUNITIES 36
4.3.1 Development of Efficient Therapy for Pancreatic Cancer Treatment 36
4.4 FUTURE TRENDS 36
4.4.1 Rapid Adoption of Combination Therapy Over Monotherapy 36
4.5 IMPACT ANALYSIS 37

5. PANCREATIC CANCER THERAPY MARKET - GLOBAL ANALYSIS 38
5.1 GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS 38
5.2 GLOBAL PANCREATIC CANCER THERAPY MARKET, BY GEOGRAPHY - FORECASTS AND ANALYSIS 39
5.3 EXPERT OPINIONS 40

6. PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY TYPE 41
6.1 OVERVIEW 41
6.1.1 Endocrine Pancreatic Cancer 42
6.1.2 Overview 42
6.1.3 Global Endocrine Pancreatic Cancer Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 42
6.1.4 Exocrine Pancreatic Cancer 43
6.1.4.1 Overview 43
6.1.4.2 Global Exocrine Pancreatic Cancer Therapy market Revenue and Forecasts to 2025 (US$ Mn) 43

7. GLOBAL PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY THERAPY 44
7.1 OVERVIEW 44
7.2 BIOLOGIC THERAPY 45
7.2.1 Overview 45
7.2.2 Global Biologic Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 45
7.3 CHEMOTHERAPY 46
7.3.1 Overview 46
7.3.2 Global Chemotherapy Market Revenue and Forecasts to 2025 (US$ Mn) 46
7.4 OTHERS 47
7.4.1 Overview 47
7.4.2 Global Others Market Revenue and Forecasts to 2025 (US$ Mn) 47

8. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 48
8.1 OVERVIEW 48
8.2 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
8.3 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
8.4 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
8.5 NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
8.6 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 51
8.7 US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
8.7.1 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 52
8.7.2 US Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 53
8.8 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
8.9 CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
8.9.1 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 55
8.9.2 Canada Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 55
8.10 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
8.11 MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
8.11.1 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 57
8.11.2 Mexico Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 57

9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 58
9.1 OVERVIEW 58
9.2 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
9.3 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
9.4 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
9.5 EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
9.6 GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 61
9.6.1 Germany Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 62
9.6.2 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 62
9.6.3 Germany Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 63
9.7 UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 63
9.7.1 UK Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 64
9.7.2 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 64
9.7.3 UK Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 65
9.8 FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
9.8.1 France Pancreatic Cancer Therapy Market Revenue and Forecasts To 2025 (US$ Mn) 66
9.8.2 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 67
9.8.3 France Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 67

10. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 68
10.1 OVERVIEW 68
10.2 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
10.3 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
10.4 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
10.5 ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
10.6 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
10.7 JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
10.7.1 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 72
10.7.2 Japan Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 72
10.8 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
10.9 CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
10.9.1 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 74
10.9.2 China Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 74
10.10 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 75
10.11 INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
10.11.1 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 76
10.11.2 India Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 77

11. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 78
11.1 OVERVIEW 78
11.2 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
11.3 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
11.4 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
11.5 MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
11.6 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
11.7 UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
11.7.1 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 82
11.7.2 UAE Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 82
11.8 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 82
11.9 SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
11.9.1 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 83
11.9.2 Saudi Arabia Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 84
11.10 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 84
11.11 SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
11.11.1 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 85
11.11.2 South Africa Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 86

12. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 87
12.1 OVERVIEW 87
12.2 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
12.3 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
12.4 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
12.5 SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
12.6 BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
12.6.1 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025 (US$ Mn) 90
12.6.2 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Type (US$ Mn) 91
12.6.3 Brazil Pancreatic Cancer Therapy Market Revenue And Forecasts to 2025, By Therapy (US$ Mn) 91

13. PANCREATIC CANCER THERAPY MARKET -INDUSTRY LANDSCAPE 92
13.1 OVERVIEW 92
13.2 GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
13.3 ORGANIC DEVELOPMENTS 92
13.3.1 Overview 92
13.4 ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
13.5 CLINICAL TRIALS 93
13.5.1 Recent Clinical Trials By Players In The Pancreatic Cancer Therapy Market 93
13.6 PRODUCT APPROVAL 94
13.6.1 Recent Product Approval By Players In The Pancreatic Cancer Therapy Market 94
13.7 OTHERS 94
13.7.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 94
13.8 INORGANIC DEVELOPMENTS 95
13.8.1 Overview 95
13.9 INORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95
13.10 COLLABORATION 96
13.10.1 Recent Collaborations by Players in the Pancreatic Cancer Therapy Market 96
13.11 OTHERS 96
13.11.1 Other Organic Developments In The Pancreatic Cancer Therapy Market 96

14. PANCREATIC CANCER THERAPY MARKET -KEY COMPANY PROFILES 97
14.1 ELI LILLY AND COMPANY 97
14.1.1 Key Facts 97
14.1.2 Business Description 97
14.1.3 Financial Overview 98
14.1.4 Product Portfolio 98
14.1.5 SWOT Analysis 98
14.1.6 Key Developments 99
14.2 F. HOFFMANN-LA ROCHE LTD. 100
14.2.1 Key Facts 100
14.2.2 Business Description 100
14.2.3 Financial Overview 101
14.2.4 Product Portfolio 101
14.2.5 Product Pipeline 101
14.2.6 SWOT Analysis 102
14.2.7 Key Developments 102
14.3 AMGEN INC. 103
14.3.1 Key Facts 103
14.3.2 Business Description 103
14.3.3 Financial Overview 104
14.3.4 Product Portfolio 104
14.3.5 Product Pipeline 104
14.3.6 SWOT Analysis 105
14.3.7 Key Developments 105
14.4 NOVARTIS AG 106
14.4.1 Key Facts 106
14.4.2 Business Description 106
14.4.3 Financial Overview 107
14.4.4 Product Portfolio 107
14.4.5 Product Pipeline 107
14.4.6 SWOT Analysis 108
14.4.7 Key Developments 108
14.5 CELGENE CORPORATION 109
14.5.1 Key Facts 109
14.5.2 Business Description 109
14.5.3 Financial Overview 110
14.5.4 Product Portfolio 110
14.5.5 SWOT Analysis 110
14.5.6 Key Developments 111
14.6 MERCK & CO., INC. 112
14.6.1 Key Facts 112
14.6.2 Business Description 112
14.6.3 Financial Overview 113
14.6.4 Product Portfolio 113
14.6.5 Product Pipeline 113
14.6.6 SWOT Analysis 114
14.6.7 Key Developments 114
14.7 PHARMACYTE BIOTECH INC. 116
14.7.1 Key Facts 116
14.7.2 Business Description 116
14.7.3 Financial Overview 117
14.7.4 Product Portfolio 117
14.7.5 SWOT Analysis 117
14.7.6 Key Developments 118
14.8 CLOVIS ONCOLOGY 119
14.8.1 Key Facts 119
14.8.2 Business Description 119
14.8.3 Financial Overview 120
14.8.4 Product Portfolio 120
14.8.5 SWOT Analysis 120
14.8.6 Key Developments 120
14.9 TEVA PHARMACEUTICAL INDUSTRIES LTD 121
14.9.1 Key Facts 121
14.9.2 Business Description 121
14.9.3 Financial Overview 122
14.9.4 Product Portfolio 122
14.9.5 SWOT Analysis 122
14.9.6 Key Developments 122
14.10 PFIZER INC. 123
14.10.1 Key Facts 123
14.10.2 Business Description 123
14.10.3 Financial Overview 124
14.10.4 Product Portfolio 124
14.10.5 SWOT Analysis 124
14.10.6 Key Developments 125

15. APPENDIX 126
15.1 ABOUT THE INSIGHT PARTNERS 126
15.2 GLOSSARY OF TERMS 127
15.3 METHODOLOGY 129
15.3.1 Coverage 130
15.3.2 Secondary Research 131
15.3.3 Primary Research 131

LIST OF TABLES

TABLE 1. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 49
TABLE 2. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 50
TABLE 3. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 52
TABLE 4. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 53
TABLE 5. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 55
TABLE 6. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 55
TABLE 7. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 57
TABLE 8. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 57
TABLE 9. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 59
TABLE 10. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 60
TABLE 11. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 62
TABLE 12. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 63
TABLE 13. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 64
TABLE 14. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 65
TABLE 15. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 67
TABLE 16. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 67
TABLE 17. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 69
TABLE 18. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 70
TABLE 19. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 70
TABLE 20. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 72
TABLE 21. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 72
TABLE 22. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 74
TABLE 23. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 74
TABLE 24. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 76
TABLE 25. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 77
TABLE 26. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 79
TABLE 27. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 80
TABLE 28. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 82
TABLE 29. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 82
TABLE 30. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 83
TABLE 31. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 84
TABLE 32. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 85
TABLE 33. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 86
TABLE 34. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 88
TABLE 35. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$ MN) 89
TABLE 36. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY TYPE (US$ MN) 91
TABLE 37. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY THERAPY (US$MN) 91
TABLE 38. RECENT CLINICAL TRIALS IN THE PANCREATIC CANCER THERAPY MARKET 93
TABLE 39. RECENT PRODUCT APPROVAL IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 40. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 94
TABLE 41. RECENT COLLABORATIONS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 42. OTHER ORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET 96
TABLE 43. GLOSSARY OF TERMS, PANCREATIC CANCER THERAPY MARKET 127

LIST OF FIGURES

FIGURE 1. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET, REVENUE (US$ MN), BY GEOGRAPHY 2018 & 2025 19
FIGURE 2. GLOBAL PANCREATIC CANCER THERAPY MARKET BY TYPE, MARKET SHARE (%), 2017 20
FIGURE 3. GLOBAL PANCREATIC CANCER THERAPY MARKET BY THERAPY, MARKET SHARE (%), 2017 20
FIGURE 4. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION 21
FIGURE 5. GLOBAL PANCREATIC CANCER THERAPY MARKET SEGMENTATION, BY REGION 22
FIGURE 6. NORTH AMERICA PEST ANALYSIS 24
FIGURE 7. EUROPE PEST ANALYSIS 26
FIGURE 8. ASIA PACIFIC PEST ANALYSIS 28
FIGURE 9. MIDDLE EAST AND AFRICA PEST ANALYSIS 30
FIGURE 10. SOUTH AND CENTRAL AMERICA PEST ANALYSIS 32
FIGURE 11. PANCREATIC CANCER THERAPY MARKET IMPACT ANALYSIS OF DRIVER AND RESTRAINTS 37
FIGURE 12. GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS - 2017- 2025 38
FIGURE 13. GLOBAL PANCREATIC CANCER THERAPY MARKET - BY GEOGRAPHY FORECASTS AND ANALYSIS - 2017- 2025 39
FIGURE 14. GLOBAL PANCREATIC CANCER THERAPY MARKET BREAKDOWN, BY PRODUCT 2017 & 2025 (%) 41
FIGURE 15. GLOBAL ENDOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 42
FIGURE 16. GLOBAL EXOCRINE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 43
FIGURE 17. GLOBAL PANCREATIC CANCER THERAPY MARKET SHARE, BY THERAPY 2017 & 2025 (%) 44
FIGURE 18. GLOBAL BIOLOGIC THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 45
FIGURE 19. GLOBAL CHEMOTHERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 46
FIGURE 20. GLOBAL OTHERS MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 47
FIGURE 21. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 48
FIGURE 22. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 49
FIGURE 23. NORTH AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 50
FIGURE 24. US PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 52
FIGURE 25. CANADA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 54
FIGURE 26. MEXICO PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 56
FIGURE 27. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 58
FIGURE 28. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 59
FIGURE 29. EUROPE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (%) 60
FIGURE 30. GERMANY PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 62
FIGURE 31. UK PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 64
FIGURE 32. FRANCE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 66
FIGURE 33. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 68
FIGURE 34. ASIA PACIFIC PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 69
FIGURE 35. JAPAN PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 71
FIGURE 36. CHINA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 73
FIGURE 37. INDIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 76
FIGURE 38. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 78
FIGURE 39. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 79
FIGURE 40. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025, BY COUNTRY (US$ MN) 80
FIGURE 41. UAE PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 81
FIGURE 42. SAUDI ARABIA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 83
FIGURE 43. SOUTH AFRICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 85
FIGURE 44. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE, BY COUNTRY (2017) (US$ MN) 87
FIGURE 45. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 88
FIGURE 46. SOUTH AND CENTRAL AMERICA PANCREATIC CANCER THERAPY MARKET SHARE, BY COUNTRY (2017 & 2025) (%) 89
FIGURE 47. BRAZIL PANCREATIC CANCER THERAPY MARKET REVENUE AND FORECASTS TO 2025 (US$ MN) 90
FIGURE 48. GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 92
FIGURE 49. ORGANIC GROWTH STRATEGIES IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 93
FIGURE 50. INORGANIC DEVELOPMENTS IN THE PANCREATIC CANCER THERAPY MARKET, 2015-2018 95

The List of Companies

1. Eli Lilly and Company
2. F. Hoffmann-La Roche AG
3. Celgene Corporation
4. Amgen Inc.
5. Novartis AG
6. Pharmacyte Biotech Inc.
7. Clovis Oncology
8. Teva Pharmaceutical Industries Ltd.
9. Pfizer Inc.
10. Merck & Co., Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pancreatic cancer therapy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global pancreatic cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPMD00002009
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing